AVELUMAB was accepted for Priority Review by FDA. The drug is sponsored by Merck KGaA, Darmstadt, Germany, which in the US and Canada operates as EMD Serono. The drug is being developed through an alliance between Merck KGaA and and Pfizer Inc. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
